nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—IKBKE—TRAF6 mediated IRF7 activation—IFNA1—vaginal cancer	0.011	0.0405	CbGpPWpGaD
Crizotinib—TBK1—TRAF6 mediated IRF7 activation—IFNA1—vaginal cancer	0.0082	0.0301	CbGpPWpGaD
Crizotinib—ROS1—Spinal Cord Injury—IL2—vaginal cancer	0.00642	0.0236	CbGpPWpGaD
Crizotinib—TYK2—Regulation of IFNA signaling—IFNA1—vaginal cancer	0.0057	0.0209	CbGpPWpGaD
Crizotinib—IKBKE—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IFNA1—vaginal cancer	0.00543	0.0199	CbGpPWpGaD
Crizotinib—IKBKE—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00447	0.0164	CbGpPWpGaD
Crizotinib—TBK1—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IFNA1—vaginal cancer	0.00404	0.0148	CbGpPWpGaD
Crizotinib—MAP3K3—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.0038	0.014	CbGpPWpGaD
Crizotinib—JAK3—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00359	0.0132	CbGpPWpGaD
Crizotinib—JAK3—Interleukin receptor SHC signaling—IL2—vaginal cancer	0.0035	0.0128	CbGpPWpGaD
Crizotinib—IKBKE—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00349	0.0128	CbGpPWpGaD
Crizotinib—TYK2—Interferon Signaling—EIF4A3—vaginal cancer	0.00341	0.0125	CbGpPWpGaD
Crizotinib—TBK1—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00332	0.0122	CbGpPWpGaD
Crizotinib—JAK3—IL2 signaling events mediated by STAT5—IL2—vaginal cancer	0.00331	0.0122	CbGpPWpGaD
Crizotinib—RIPK2—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.0032	0.0117	CbGpPWpGaD
Crizotinib—PTK2B—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00315	0.0116	CbGpPWpGaD
Crizotinib—JAK3—IL2 signaling events mediated by PI3K—IL2—vaginal cancer	0.0028	0.0103	CbGpPWpGaD
Crizotinib—TYK2—Interferon alpha/beta signaling—IFNA1—vaginal cancer	0.00274	0.0101	CbGpPWpGaD
Crizotinib—IGF1R—SHP2 signaling—IL2—vaginal cancer	0.0027	0.00992	CbGpPWpGaD
Crizotinib—TBK1—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.0026	0.00953	CbGpPWpGaD
Crizotinib—TEK—SHP2 signaling—IL2—vaginal cancer	0.00259	0.00951	CbGpPWpGaD
Crizotinib—JAK2—Interferon Signaling—EIF4A3—vaginal cancer	0.00258	0.00949	CbGpPWpGaD
Crizotinib—JAK3—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00253	0.00928	CbGpPWpGaD
Crizotinib—YES1—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00247	0.00908	CbGpPWpGaD
Crizotinib—JAK3—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00244	0.00895	CbGpPWpGaD
Crizotinib—TYRO3—female reproductive system—vaginal cancer	0.00237	0.00325	CbGeAlD
Crizotinib—FER—female reproductive system—vaginal cancer	0.00237	0.00325	CbGeAlD
Crizotinib—ALK—female reproductive system—vaginal cancer	0.00237	0.00325	CbGeAlD
Crizotinib—NUAK2—mammalian vulva—vaginal cancer	0.00237	0.00325	CbGeAlD
Crizotinib—MERTK—Hemostasis—IFNA1—vaginal cancer	0.00236	0.00868	CbGpPWpGaD
Crizotinib—TYK2—IL27-mediated signaling events—IL2—vaginal cancer	0.00236	0.00865	CbGpPWpGaD
Crizotinib—ACVR1—mammalian vulva—vaginal cancer	0.00235	0.00323	CbGeAlD
Crizotinib—MAP3K12—mammalian vulva—vaginal cancer	0.00235	0.00323	CbGeAlD
Crizotinib—IRAK1—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00235	0.00861	CbGpPWpGaD
Crizotinib—JAK3—female gonad—vaginal cancer	0.00232	0.00319	CbGeAlD
Crizotinib—MAP3K19—female reproductive system—vaginal cancer	0.00232	0.00319	CbGeAlD
Crizotinib—BMPR1B—female reproductive system—vaginal cancer	0.00232	0.00319	CbGeAlD
Crizotinib—JAK3—Interleukin-2 signaling—IL2—vaginal cancer	0.00231	0.00849	CbGpPWpGaD
Crizotinib—MAP3K2—uterine cervix—vaginal cancer	0.0023	0.00316	CbGeAlD
Crizotinib—TXK—Immune System—EIF4A3—vaginal cancer	0.0023	0.00844	CbGpPWpGaD
Crizotinib—DCLK1—vagina—vaginal cancer	0.00229	0.00315	CbGeAlD
Crizotinib—BMP2K—endometrium—vaginal cancer	0.00229	0.00315	CbGeAlD
Crizotinib—RPS6KB1—IL2 signaling events mediated by PI3K—IL2—vaginal cancer	0.00228	0.00838	CbGpPWpGaD
Crizotinib—STK4—female gonad—vaginal cancer	0.00228	0.00313	CbGeAlD
Crizotinib—TYK2—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00228	0.00836	CbGpPWpGaD
Crizotinib—TNK2—female reproductive system—vaginal cancer	0.00227	0.00312	CbGeAlD
Crizotinib—IGF1R—female reproductive system—vaginal cancer	0.00227	0.00312	CbGeAlD
Crizotinib—JAK3—G beta:gamma signalling through PI3Kgamma—IL2—vaginal cancer	0.00227	0.00834	CbGpPWpGaD
Crizotinib—PTK2—epithelium—vaginal cancer	0.00227	0.00312	CbGeAlD
Crizotinib—LIMK2—uterus—vaginal cancer	0.00226	0.00311	CbGeAlD
Crizotinib—PTK2—uterine cervix—vaginal cancer	0.00225	0.0031	CbGeAlD
Crizotinib—TBK1—uterine cervix—vaginal cancer	0.00225	0.0031	CbGeAlD
Crizotinib—MAP4K2—female reproductive system—vaginal cancer	0.00224	0.00308	CbGeAlD
Crizotinib—ACVR1—uterus—vaginal cancer	0.00224	0.00308	CbGeAlD
Crizotinib—TYK2—uterine cervix—vaginal cancer	0.00224	0.00307	CbGeAlD
Crizotinib—JAK3—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00224	0.00821	CbGpPWpGaD
Crizotinib—RIPK2—urethra—vaginal cancer	0.00223	0.00306	CbGeAlD
Crizotinib—PTK2B—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00222	0.00816	CbGpPWpGaD
Crizotinib—TIE1—female reproductive system—vaginal cancer	0.00221	0.00304	CbGeAlD
Crizotinib—STK3—female reproductive system—vaginal cancer	0.00221	0.00304	CbGeAlD
Crizotinib—IRAK1—uterine cervix—vaginal cancer	0.00221	0.00303	CbGeAlD
Crizotinib—RIPK2—endometrium—vaginal cancer	0.00219	0.00302	CbGeAlD
Crizotinib—RPS6KB1—epithelium—vaginal cancer	0.00219	0.003	CbGeAlD
Crizotinib—RPS6KB1—uterine cervix—vaginal cancer	0.00217	0.00298	CbGeAlD
Crizotinib—JAK3—G-protein beta:gamma signalling—IL2—vaginal cancer	0.00216	0.00795	CbGpPWpGaD
Crizotinib—AURKA—female reproductive system—vaginal cancer	0.00216	0.00296	CbGeAlD
Crizotinib—EPHA4—urethra—vaginal cancer	0.00216	0.00296	CbGeAlD
Crizotinib—LCK—uterine cervix—vaginal cancer	0.00215	0.00296	CbGeAlD
Crizotinib—FER—female gonad—vaginal cancer	0.00215	0.00296	CbGeAlD
Crizotinib—TYRO3—female gonad—vaginal cancer	0.00215	0.00296	CbGeAlD
Crizotinib—AXL—uterine cervix—vaginal cancer	0.00214	0.00295	CbGeAlD
Crizotinib—RPS6KB1—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00214	0.00787	CbGpPWpGaD
Crizotinib—EPHA5—vagina—vaginal cancer	0.00214	0.00294	CbGeAlD
Crizotinib—FER—vagina—vaginal cancer	0.00214	0.00294	CbGeAlD
Crizotinib—TESK1—female reproductive system—vaginal cancer	0.00214	0.00294	CbGeAlD
Crizotinib—TNK1—female gonad—vaginal cancer	0.00213	0.00293	CbGeAlD
Crizotinib—TNK1—vagina—vaginal cancer	0.00212	0.00291	CbGeAlD
Crizotinib—BMPR1B—female gonad—vaginal cancer	0.00211	0.0029	CbGeAlD
Crizotinib—MAP4K1—vagina—vaginal cancer	0.0021	0.00288	CbGeAlD
Crizotinib—PTK2—urethra—vaginal cancer	0.00207	0.00284	CbGeAlD
Crizotinib—TBK1—urethra—vaginal cancer	0.00207	0.00284	CbGeAlD
Crizotinib—TNK2—female gonad—vaginal cancer	0.00207	0.00284	CbGeAlD
Crizotinib—IGF1R—female gonad—vaginal cancer	0.00207	0.00284	CbGeAlD
Crizotinib—JAK3—IL2-mediated signaling events—IL2—vaginal cancer	0.00207	0.00759	CbGpPWpGaD
Crizotinib—EPHB4—epithelium—vaginal cancer	0.00207	0.00284	CbGeAlD
Crizotinib—SLK—uterine cervix—vaginal cancer	0.00206	0.00284	CbGeAlD
Crizotinib—RPS6KB1—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00206	0.00757	CbGpPWpGaD
Crizotinib—IGF1R—vagina—vaginal cancer	0.00206	0.00283	CbGeAlD
Crizotinib—TYK2—urethra—vaginal cancer	0.00206	0.00283	CbGeAlD
Crizotinib—JAK2—epithelium—vaginal cancer	0.00205	0.00282	CbGeAlD
Crizotinib—EPHA4—mammalian vulva—vaginal cancer	0.00205	0.00282	CbGeAlD
Crizotinib—EPHB4—uterine cervix—vaginal cancer	0.00205	0.00282	CbGeAlD
Crizotinib—MAP4K2—female gonad—vaginal cancer	0.00204	0.0028	CbGeAlD
Crizotinib—TBK1—endometrium—vaginal cancer	0.00204	0.0028	CbGeAlD
Crizotinib—JAK2—uterine cervix—vaginal cancer	0.00204	0.0028	CbGeAlD
Crizotinib—LIMK2—female reproductive system—vaginal cancer	0.00203	0.00279	CbGeAlD
Crizotinib—PTK2B—Interleukin-2 signaling—IL2—vaginal cancer	0.00203	0.00745	CbGpPWpGaD
Crizotinib—EPHA2—epithelium—vaginal cancer	0.00203	0.00279	CbGeAlD
Crizotinib—MAP4K2—vagina—vaginal cancer	0.00203	0.00279	CbGeAlD
Crizotinib—TYK2—endometrium—vaginal cancer	0.00202	0.00278	CbGeAlD
Crizotinib—STK3—female gonad—vaginal cancer	0.00201	0.00277	CbGeAlD
Crizotinib—TIE1—female gonad—vaginal cancer	0.00201	0.00277	CbGeAlD
Crizotinib—MAP3K12—female reproductive system—vaginal cancer	0.00201	0.00277	CbGeAlD
Crizotinib—FLT3—female reproductive system—vaginal cancer	0.00201	0.00277	CbGeAlD
Crizotinib—ACVR1—female reproductive system—vaginal cancer	0.00201	0.00277	CbGeAlD
Crizotinib—EPHA2—uterine cervix—vaginal cancer	0.00201	0.00276	CbGeAlD
Crizotinib—STK3—vagina—vaginal cancer	0.002	0.00275	CbGeAlD
Crizotinib—RPS6KB1—urethra—vaginal cancer	0.00199	0.00274	CbGeAlD
Crizotinib—LCK—urethra—vaginal cancer	0.00198	0.00272	CbGeAlD
Crizotinib—FGR—urethra—vaginal cancer	0.00198	0.00272	CbGeAlD
Crizotinib—TEK—epithelium—vaginal cancer	0.00198	0.00272	CbGeAlD
Crizotinib—STK35—female reproductive system—vaginal cancer	0.00197	0.00271	CbGeAlD
Crizotinib—AXL—urethra—vaginal cancer	0.00197	0.00271	CbGeAlD
Crizotinib—TBK1—mammalian vulva—vaginal cancer	0.00197	0.00271	CbGeAlD
Crizotinib—IRAK1—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00197	0.00722	CbGpPWpGaD
Crizotinib—MAP3K3—uterine cervix—vaginal cancer	0.00196	0.0027	CbGeAlD
Crizotinib—MAP4K5—uterine cervix—vaginal cancer	0.00196	0.0027	CbGeAlD
Crizotinib—AURKA—female gonad—vaginal cancer	0.00196	0.0027	CbGeAlD
Crizotinib—RPS6KB1—endometrium—vaginal cancer	0.00196	0.00269	CbGeAlD
Crizotinib—TYK2—mammalian vulva—vaginal cancer	0.00196	0.00269	CbGeAlD
Crizotinib—EPHA4—uterus—vaginal cancer	0.00195	0.00269	CbGeAlD
Crizotinib—JAK3—SHP2 signaling—IL2—vaginal cancer	0.00195	0.00717	CbGpPWpGaD
Crizotinib—AURKA—vagina—vaginal cancer	0.00195	0.00268	CbGeAlD
Crizotinib—FGR—endometrium—vaginal cancer	0.00195	0.00268	CbGeAlD
Crizotinib—TESK1—female gonad—vaginal cancer	0.00195	0.00267	CbGeAlD
Crizotinib—AXL—endometrium—vaginal cancer	0.00194	0.00267	CbGeAlD
Crizotinib—TESK1—vagina—vaginal cancer	0.00193	0.00266	CbGeAlD
Crizotinib—IRAK1—mammalian vulva—vaginal cancer	0.00193	0.00265	CbGeAlD
Crizotinib—MAP3K2—uterus—vaginal cancer	0.00192	0.00263	CbGeAlD
Crizotinib—BMP2K—female reproductive system—vaginal cancer	0.0019	0.00261	CbGeAlD
Crizotinib—SLK—urethra—vaginal cancer	0.0019	0.00261	CbGeAlD
Crizotinib—RPS6KB1—mammalian vulva—vaginal cancer	0.0019	0.00261	CbGeAlD
Crizotinib—MERTK—female gonad—vaginal cancer	0.00189	0.0026	CbGeAlD
Crizotinib—FGR—mammalian vulva—vaginal cancer	0.00188	0.00259	CbGeAlD
Crizotinib—LCK—mammalian vulva—vaginal cancer	0.00188	0.00259	CbGeAlD
Crizotinib—EPHB4—urethra—vaginal cancer	0.00188	0.00259	CbGeAlD
Crizotinib—MERTK—vagina—vaginal cancer	0.00188	0.00258	CbGeAlD
Crizotinib—PTK2—uterus—vaginal cancer	0.00188	0.00258	CbGeAlD
Crizotinib—AXL—mammalian vulva—vaginal cancer	0.00188	0.00258	CbGeAlD
Crizotinib—EPHB6—uterine cervix—vaginal cancer	0.00187	0.00258	CbGeAlD
Crizotinib—JAK2—urethra—vaginal cancer	0.00187	0.00257	CbGeAlD
Crizotinib—SLK—endometrium—vaginal cancer	0.00187	0.00257	CbGeAlD
Crizotinib—TYK2—uterus—vaginal cancer	0.00186	0.00256	CbGeAlD
Crizotinib—EPHB4—endometrium—vaginal cancer	0.00185	0.00255	CbGeAlD
Crizotinib—LIMK2—female gonad—vaginal cancer	0.00185	0.00254	CbGeAlD
Crizotinib—EPHA2—urethra—vaginal cancer	0.00185	0.00254	CbGeAlD
Crizotinib—LYN—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00184	0.00677	CbGpPWpGaD
Crizotinib—NUAK2—female gonad—vaginal cancer	0.00184	0.00253	CbGeAlD
Crizotinib—JAK2—endometrium—vaginal cancer	0.00184	0.00253	CbGeAlD
Crizotinib—LIMK2—vagina—vaginal cancer	0.00184	0.00253	CbGeAlD
Crizotinib—NUAK2—vagina—vaginal cancer	0.00183	0.00252	CbGeAlD
Crizotinib—PTK2B—female reproductive system—vaginal cancer	0.00183	0.00252	CbGeAlD
Crizotinib—MAP3K12—female gonad—vaginal cancer	0.00183	0.00252	CbGeAlD
Crizotinib—ACVR1—female gonad—vaginal cancer	0.00183	0.00252	CbGeAlD
Crizotinib—FLT3—female gonad—vaginal cancer	0.00183	0.00252	CbGeAlD
Crizotinib—MAP3K12—vagina—vaginal cancer	0.00182	0.0025	CbGeAlD
Crizotinib—ACVR1—vagina—vaginal cancer	0.00182	0.0025	CbGeAlD
Crizotinib—EPHA2—endometrium—vaginal cancer	0.00182	0.0025	CbGeAlD
Crizotinib—RIPK2—female reproductive system—vaginal cancer	0.00182	0.0025	CbGeAlD
Crizotinib—PTK2B—IL2-mediated signaling events—IL2—vaginal cancer	0.00182	0.00667	CbGpPWpGaD
Crizotinib—YES1—uterine cervix—vaginal cancer	0.00181	0.00249	CbGeAlD
Crizotinib—SLK—mammalian vulva—vaginal cancer	0.00181	0.00248	CbGeAlD
Crizotinib—MAP4K5—urethra—vaginal cancer	0.0018	0.00248	CbGeAlD
Crizotinib—TEK—urethra—vaginal cancer	0.0018	0.00248	CbGeAlD
Crizotinib—MAP3K3—urethra—vaginal cancer	0.0018	0.00248	CbGeAlD
Crizotinib—STK10—uterine cervix—vaginal cancer	0.0018	0.00247	CbGeAlD
Crizotinib—LCK—uterus—vaginal cancer	0.00179	0.00247	CbGeAlD
Crizotinib—STK35—female gonad—vaginal cancer	0.00179	0.00247	CbGeAlD
Crizotinib—EPHB4—mammalian vulva—vaginal cancer	0.00179	0.00246	CbGeAlD
Crizotinib—TAOK3—uterine cervix—vaginal cancer	0.00179	0.00246	CbGeAlD
Crizotinib—AXL—uterus—vaginal cancer	0.00179	0.00246	CbGeAlD
Crizotinib—JAK2—IL27-mediated signaling events—IL2—vaginal cancer	0.00179	0.00656	CbGpPWpGaD
Crizotinib—STK35—vagina—vaginal cancer	0.00178	0.00245	CbGeAlD
Crizotinib—JAK2—mammalian vulva—vaginal cancer	0.00178	0.00245	CbGeAlD
Crizotinib—TYK2—IL23-mediated signaling events—IL2—vaginal cancer	0.00178	0.00653	CbGpPWpGaD
Crizotinib—TEK—endometrium—vaginal cancer	0.00177	0.00244	CbGeAlD
Crizotinib—MAP4K5—endometrium—vaginal cancer	0.00177	0.00244	CbGeAlD
Crizotinib—MAP3K3—endometrium—vaginal cancer	0.00177	0.00244	CbGeAlD
Crizotinib—EPHA2—mammalian vulva—vaginal cancer	0.00176	0.00242	CbGeAlD
Crizotinib—SRC—epithelium—vaginal cancer	0.00176	0.00242	CbGeAlD
Crizotinib—EPHA4—female reproductive system—vaginal cancer	0.00176	0.00241	CbGeAlD
Crizotinib—ABL2—female gonad—vaginal cancer	0.00175	0.0024	CbGeAlD
Crizotinib—SRC—uterine cervix—vaginal cancer	0.00174	0.0024	CbGeAlD
Crizotinib—IKBKE—Immune System—EIF4A3—vaginal cancer	0.00174	0.0064	CbGpPWpGaD
Crizotinib—ABL2—vagina—vaginal cancer	0.00174	0.00239	CbGeAlD
Crizotinib—BMP2K—female gonad—vaginal cancer	0.00173	0.00237	CbGeAlD
Crizotinib—JAK2—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00173	0.00634	CbGpPWpGaD
Crizotinib—MAP3K2—female reproductive system—vaginal cancer	0.00172	0.00237	CbGeAlD
Crizotinib—EPHB6—urethra—vaginal cancer	0.00172	0.00237	CbGeAlD
Crizotinib—SLK—uterus—vaginal cancer	0.00172	0.00236	CbGeAlD
Crizotinib—MAP3K3—mammalian vulva—vaginal cancer	0.00172	0.00236	CbGeAlD
Crizotinib—MAP4K5—mammalian vulva—vaginal cancer	0.00172	0.00236	CbGeAlD
Crizotinib—BMP2K—vagina—vaginal cancer	0.00172	0.00236	CbGeAlD
Crizotinib—EPHB4—uterus—vaginal cancer	0.00171	0.00235	CbGeAlD
Crizotinib—EPHB6—endometrium—vaginal cancer	0.0017	0.00233	CbGeAlD
Crizotinib—RIPK2—IL12-mediated signaling events—IL2—vaginal cancer	0.00169	0.00622	CbGpPWpGaD
Crizotinib—TBK1—female reproductive system—vaginal cancer	0.00169	0.00232	CbGeAlD
Crizotinib—PTK2—female reproductive system—vaginal cancer	0.00169	0.00232	CbGeAlD
Crizotinib—JAK2—Interleukin receptor SHC signaling—IL2—vaginal cancer	0.00168	0.00618	CbGpPWpGaD
Crizotinib—YES1—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00168	0.00617	CbGpPWpGaD
Crizotinib—TYK2—female reproductive system—vaginal cancer	0.00168	0.0023	CbGeAlD
Crizotinib—PTK2B—female gonad—vaginal cancer	0.00167	0.00229	CbGeAlD
Crizotinib—YES1—urethra—vaginal cancer	0.00166	0.00229	CbGeAlD
Crizotinib—PTK2B—vagina—vaginal cancer	0.00166	0.00228	CbGeAlD
Crizotinib—IRAK1—female reproductive system—vaginal cancer	0.00165	0.00227	CbGeAlD
Crizotinib—RIPK2—female gonad—vaginal cancer	0.00165	0.00227	CbGeAlD
Crizotinib—RIPK2—vagina—vaginal cancer	0.00164	0.00226	CbGeAlD
Crizotinib—TAOK3—urethra—vaginal cancer	0.00164	0.00226	CbGeAlD
Crizotinib—NTRK1—SHP2 signaling—IL2—vaginal cancer	0.00164	0.00603	CbGpPWpGaD
Crizotinib—EPHB6—mammalian vulva—vaginal cancer	0.00164	0.00225	CbGeAlD
Crizotinib—YES1—endometrium—vaginal cancer	0.00164	0.00225	CbGeAlD
Crizotinib—TEK—uterus—vaginal cancer	0.00163	0.00225	CbGeAlD
Crizotinib—MAP4K5—uterus—vaginal cancer	0.00163	0.00225	CbGeAlD
Crizotinib—RPS6KB1—female reproductive system—vaginal cancer	0.00162	0.00223	CbGeAlD
Crizotinib—TAOK3—endometrium—vaginal cancer	0.00162	0.00222	CbGeAlD
Crizotinib—FGR—female reproductive system—vaginal cancer	0.00161	0.00222	CbGeAlD
Crizotinib—AXL—female reproductive system—vaginal cancer	0.00161	0.00221	CbGeAlD
Crizotinib—EPHA4—female gonad—vaginal cancer	0.0016	0.0022	CbGeAlD
Crizotinib—EPHA4—vagina—vaginal cancer	0.00159	0.00218	CbGeAlD
Crizotinib—MAPK7—Immune System—EIF4A3—vaginal cancer	0.00159	0.00582	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—EIF4A3—vaginal cancer	0.00159	0.00582	CbGpPWpGaD
Crizotinib—YES1—mammalian vulva—vaginal cancer	0.00159	0.00218	CbGeAlD
Crizotinib—STK10—mammalian vulva—vaginal cancer	0.00157	0.00216	CbGeAlD
Crizotinib—MAP3K2—female gonad—vaginal cancer	0.00157	0.00215	CbGeAlD
Crizotinib—TAOK3—mammalian vulva—vaginal cancer	0.00156	0.00215	CbGeAlD
Crizotinib—CSF1R—uterine cervix—vaginal cancer	0.00156	0.00215	CbGeAlD
Crizotinib—EPHB4—female reproductive system—vaginal cancer	0.00154	0.00211	CbGeAlD
Crizotinib—IRAK1—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00154	0.00564	CbGpPWpGaD
Crizotinib—PTK2—female gonad—vaginal cancer	0.00154	0.00211	CbGeAlD
Crizotinib—TBK1—female gonad—vaginal cancer	0.00154	0.00211	CbGeAlD
Crizotinib—EPHA4—Spinal Cord Injury—IL2—vaginal cancer	0.00153	0.00562	CbGpPWpGaD
Crizotinib—TBK1—vagina—vaginal cancer	0.00153	0.0021	CbGeAlD
Crizotinib—PTK2—vagina—vaginal cancer	0.00153	0.0021	CbGeAlD
Crizotinib—TYK2—female gonad—vaginal cancer	0.00153	0.0021	CbGeAlD
Crizotinib—JAK2—female reproductive system—vaginal cancer	0.00152	0.0021	CbGeAlD
Crizotinib—TYK2—vagina—vaginal cancer	0.00152	0.00208	CbGeAlD
Crizotinib—LCK—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00151	0.00555	CbGpPWpGaD
Crizotinib—YES1—uterus—vaginal cancer	0.00151	0.00208	CbGeAlD
Crizotinib—EPHA2—female reproductive system—vaginal cancer	0.00151	0.00207	CbGeAlD
Crizotinib—IRAK1—female gonad—vaginal cancer	0.00151	0.00207	CbGeAlD
Crizotinib—STK10—uterus—vaginal cancer	0.0015	0.00206	CbGeAlD
Crizotinib—TAOK3—uterus—vaginal cancer	0.00149	0.00205	CbGeAlD
Crizotinib—RPS6KB1—female gonad—vaginal cancer	0.00148	0.00203	CbGeAlD
Crizotinib—TXK—Innate Immune System—IFNA1—vaginal cancer	0.00148	0.00542	CbGpPWpGaD
Crizotinib—MAP4K5—female reproductive system—vaginal cancer	0.00147	0.00202	CbGeAlD
Crizotinib—TEK—female reproductive system—vaginal cancer	0.00147	0.00202	CbGeAlD
Crizotinib—MAP3K3—female reproductive system—vaginal cancer	0.00147	0.00202	CbGeAlD
Crizotinib—RPS6KB1—vagina—vaginal cancer	0.00147	0.00202	CbGeAlD
Crizotinib—LCK—female gonad—vaginal cancer	0.00147	0.00202	CbGeAlD
Crizotinib—FGR—female gonad—vaginal cancer	0.00147	0.00202	CbGeAlD
Crizotinib—TYK2—Interleukin-2 signaling—IL2—vaginal cancer	0.00147	0.00539	CbGpPWpGaD
Crizotinib—AXL—female gonad—vaginal cancer	0.00146	0.00201	CbGeAlD
Crizotinib—FGR—vagina—vaginal cancer	0.00146	0.00201	CbGeAlD
Crizotinib—LCK—vagina—vaginal cancer	0.00146	0.00201	CbGeAlD
Crizotinib—AXL—vagina—vaginal cancer	0.00145	0.002	CbGeAlD
Crizotinib—CSF1R—urethra—vaginal cancer	0.00144	0.00198	CbGeAlD
Crizotinib—LCK—T-Cell Receptor and Co-stimulatory Signaling—IL2—vaginal cancer	0.00143	0.00526	CbGpPWpGaD
Crizotinib—MAP3K3—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00142	0.00522	CbGpPWpGaD
Crizotinib—CSF1R—endometrium—vaginal cancer	0.00142	0.00194	CbGeAlD
Crizotinib—SLK—female gonad—vaginal cancer	0.00141	0.00193	CbGeAlD
Crizotinib—RPS6KB1—Regulation of Telomerase—IL2—vaginal cancer	0.0014	0.00515	CbGpPWpGaD
Crizotinib—SLK—vagina—vaginal cancer	0.0014	0.00192	CbGeAlD
Crizotinib—EPHB4—female gonad—vaginal cancer	0.0014	0.00192	CbGeAlD
Crizotinib—LCK—IL2 signaling events mediated by STAT5—IL2—vaginal cancer	0.0014	0.00512	CbGpPWpGaD
Crizotinib—LCK—Inflammatory Response Pathway—IL2—vaginal cancer	0.0014	0.00512	CbGpPWpGaD
Crizotinib—EPHB4—vagina—vaginal cancer	0.00139	0.00191	CbGeAlD
Crizotinib—JAK2—female gonad—vaginal cancer	0.00139	0.00191	CbGeAlD
Crizotinib—JAK2—vagina—vaginal cancer	0.00138	0.0019	CbGeAlD
Crizotinib—EPHA2—female gonad—vaginal cancer	0.00137	0.00188	CbGeAlD
Crizotinib—CSF1R—mammalian vulva—vaginal cancer	0.00137	0.00188	CbGeAlD
Crizotinib—EPHA2—vagina—vaginal cancer	0.00136	0.00187	CbGeAlD
Crizotinib—YES1—female reproductive system—vaginal cancer	0.00136	0.00187	CbGeAlD
Crizotinib—LYN—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00135	0.00497	CbGpPWpGaD
Crizotinib—JAK2—IL23-mediated signaling events—IL2—vaginal cancer	0.00135	0.00495	CbGpPWpGaD
Crizotinib—STK10—female reproductive system—vaginal cancer	0.00135	0.00185	CbGeAlD
Crizotinib—JAK3—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00134	0.00492	CbGpPWpGaD
Crizotinib—TAOK3—female reproductive system—vaginal cancer	0.00134	0.00184	CbGeAlD
Crizotinib—MAP3K3—female gonad—vaginal cancer	0.00134	0.00184	CbGeAlD
Crizotinib—MAP4K5—female gonad—vaginal cancer	0.00134	0.00184	CbGeAlD
Crizotinib—TEK—female gonad—vaginal cancer	0.00134	0.00184	CbGeAlD
Crizotinib—MAP4K5—vagina—vaginal cancer	0.00133	0.00183	CbGeAlD
Crizotinib—MAP3K3—vagina—vaginal cancer	0.00133	0.00183	CbGeAlD
Crizotinib—SRC—female reproductive system—vaginal cancer	0.00131	0.00179	CbGeAlD
Crizotinib—CSF1R—uterus—vaginal cancer	0.0013	0.00179	CbGeAlD
Crizotinib—TBK1—Immune System—EIF4A3—vaginal cancer	0.00129	0.00475	CbGpPWpGaD
Crizotinib—EPHB6—female gonad—vaginal cancer	0.00128	0.00176	CbGeAlD
Crizotinib—TYK2—Interferon Signaling—IFNA1—vaginal cancer	0.00128	0.00468	CbGpPWpGaD
Crizotinib—EPHB6—vagina—vaginal cancer	0.00127	0.00175	CbGeAlD
Crizotinib—JAK2—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00127	0.00465	CbGpPWpGaD
Crizotinib—MAP3K3—Signaling by Interleukins—IL2—vaginal cancer	0.00126	0.00462	CbGpPWpGaD
Crizotinib—LYN—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00125	0.0046	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—EIF4A3—vaginal cancer	0.00124	0.00456	CbGpPWpGaD
Crizotinib—ABL1—uterine cervix—vaginal cancer	0.00124	0.0017	CbGeAlD
Crizotinib—YES1—female gonad—vaginal cancer	0.00124	0.0017	CbGeAlD
Crizotinib—YES1—vagina—vaginal cancer	0.00123	0.00169	CbGeAlD
Crizotinib—STK10—female gonad—vaginal cancer	0.00122	0.00168	CbGeAlD
Crizotinib—ABL1—Factors involved in megakaryocyte development and platelet production—IFNA1—vaginal cancer	0.00122	0.00449	CbGpPWpGaD
Crizotinib—TAOK3—female gonad—vaginal cancer	0.00122	0.00168	CbGeAlD
Crizotinib—STK10—vagina—vaginal cancer	0.00122	0.00167	CbGeAlD
Crizotinib—TAOK3—vagina—vaginal cancer	0.00121	0.00167	CbGeAlD
Crizotinib—TYK2—IL12-mediated signaling events—IL2—vaginal cancer	0.00121	0.00443	CbGpPWpGaD
Crizotinib—RIPK2—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00119	0.00439	CbGpPWpGaD
Crizotinib—SRC—female gonad—vaginal cancer	0.00119	0.00163	CbGeAlD
Crizotinib—JAK3—Signaling by Interleukins—IL2—vaginal cancer	0.00119	0.00436	CbGpPWpGaD
Crizotinib—LCK—IL2 signaling events mediated by PI3K—IL2—vaginal cancer	0.00118	0.00433	CbGpPWpGaD
Crizotinib—PTK2B—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00118	0.00432	CbGpPWpGaD
Crizotinib—JAK2—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00117	0.00431	CbGpPWpGaD
Crizotinib—CSF1R—female reproductive system—vaginal cancer	0.00117	0.00161	CbGeAlD
Crizotinib—JAK3—Immune System—EIF4A3—vaginal cancer	0.00117	0.0043	CbGpPWpGaD
Crizotinib—JAK2—Factors involved in megakaryocyte development and platelet production—IFNA1—vaginal cancer	0.00115	0.00422	CbGpPWpGaD
Crizotinib—LYN—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00115	0.00422	CbGpPWpGaD
Crizotinib—ABL1—urethra—vaginal cancer	0.00114	0.00156	CbGeAlD
Crizotinib—ABL1—endometrium—vaginal cancer	0.00112	0.00154	CbGeAlD
Crizotinib—IKBKE—Innate Immune System—IFNA1—vaginal cancer	0.00112	0.00411	CbGpPWpGaD
Crizotinib—JAK2—Interleukin-2 signaling—IL2—vaginal cancer	0.00111	0.00408	CbGpPWpGaD
Crizotinib—TEK—Hemostasis—IFNA1—vaginal cancer	0.00111	0.00407	CbGpPWpGaD
Crizotinib—JAK2—G beta:gamma signalling through PI3Kgamma—IL2—vaginal cancer	0.00109	0.00402	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—EIF4A3—vaginal cancer	0.00109	0.00399	CbGpPWpGaD
Crizotinib—ABL1—mammalian vulva—vaginal cancer	0.00108	0.00149	CbGeAlD
Crizotinib—JAK2—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00108	0.00395	CbGpPWpGaD
Crizotinib—CSF1R—female gonad—vaginal cancer	0.00107	0.00147	CbGeAlD
Crizotinib—LCK—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00107	0.00391	CbGpPWpGaD
Crizotinib—CSF1R—vagina—vaginal cancer	0.00106	0.00146	CbGeAlD
Crizotinib—RIPK2—Signaling by Interleukins—IL2—vaginal cancer	0.00106	0.00389	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—EIF4A3—vaginal cancer	0.00104	0.00383	CbGpPWpGaD
Crizotinib—PTK2B—Signaling by Interleukins—IL2—vaginal cancer	0.00104	0.00383	CbGpPWpGaD
Crizotinib—JAK2—G-protein beta:gamma signalling—IL2—vaginal cancer	0.00104	0.00383	CbGpPWpGaD
Crizotinib—ABL1—uterus—vaginal cancer	0.00103	0.00142	CbGeAlD
Crizotinib—PTK2B—Immune System—EIF4A3—vaginal cancer	0.00103	0.00378	CbGpPWpGaD
Crizotinib—MAPK7—Innate Immune System—IFNA1—vaginal cancer	0.00102	0.00374	CbGpPWpGaD
Crizotinib—LIMK1—Innate Immune System—IFNA1—vaginal cancer	0.00102	0.00374	CbGpPWpGaD
Crizotinib—BLK—Immune System—EIF4A3—vaginal cancer	0.001	0.00369	CbGpPWpGaD
Crizotinib—FGR—Immune System—EIF4A3—vaginal cancer	0.001	0.00367	CbGpPWpGaD
Crizotinib—MERTK—Hemostasis—IL2—vaginal cancer	0.000978	0.00359	CbGpPWpGaD
Crizotinib—LCK—Interleukin-2 signaling—IL2—vaginal cancer	0.000974	0.00358	CbGpPWpGaD
Crizotinib—JAK2—Interferon Signaling—IFNA1—vaginal cancer	0.000966	0.00355	CbGpPWpGaD
Crizotinib—PTK2—Corticotropin-releasing hormone—IL2—vaginal cancer	0.000944	0.00347	CbGpPWpGaD
Crizotinib—LCK—GPVI-mediated activation cascade—IL2—vaginal cancer	0.000942	0.00346	CbGpPWpGaD
Crizotinib—JAK2—SHP2 signaling—IL2—vaginal cancer	0.00094	0.00345	CbGpPWpGaD
Crizotinib—ABL1—female reproductive system—vaginal cancer	0.000927	0.00127	CbGeAlD
Crizotinib—YES1—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000925	0.00339	CbGpPWpGaD
Crizotinib—JAK2—IL12-mediated signaling events—IL2—vaginal cancer	0.000915	0.00336	CbGpPWpGaD
Crizotinib—ABL1—Regulation of Telomerase—IL2—vaginal cancer	0.00088	0.00323	CbGpPWpGaD
Crizotinib—SRC—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.000877	0.00322	CbGpPWpGaD
Crizotinib—IRAK1—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000877	0.00322	CbGpPWpGaD
Crizotinib—LCK—IL2-mediated signaling events—IL2—vaginal cancer	0.000872	0.0032	CbGpPWpGaD
Crizotinib—TXK—Immune System—IFNA1—vaginal cancer	0.00086	0.00316	CbGpPWpGaD
Crizotinib—TYK2—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000851	0.00313	CbGpPWpGaD
Crizotinib—ABL1—female gonad—vaginal cancer	0.000843	0.00116	CbGeAlD
Crizotinib—ABL1—vagina—vaginal cancer	0.000838	0.00115	CbGeAlD
Crizotinib—JAK3—Hemostasis—IFNA1—vaginal cancer	0.000835	0.00307	CbGpPWpGaD
Crizotinib—TBK1—Innate Immune System—IFNA1—vaginal cancer	0.000831	0.00305	CbGpPWpGaD
Crizotinib—LCK—SHP2 signaling—IL2—vaginal cancer	0.000823	0.00302	CbGpPWpGaD
Crizotinib—YES1—Signaling by Interleukins—IL2—vaginal cancer	0.000819	0.00301	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EIF4A3—vaginal cancer	0.000819	0.00301	CbGpPWpGaD
Crizotinib—YES1—Immune System—EIF4A3—vaginal cancer	0.000808	0.00297	CbGpPWpGaD
Crizotinib—LCK—IL12-mediated signaling events—IL2—vaginal cancer	0.000801	0.00294	CbGpPWpGaD
Crizotinib—IRAK1—Signaling by Interleukins—IL2—vaginal cancer	0.000777	0.00285	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EIF4A3—vaginal cancer	0.000766	0.00281	CbGpPWpGaD
Crizotinib—TYK2—Signaling by Interleukins—IL2—vaginal cancer	0.000754	0.00277	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EIF4A3—vaginal cancer	0.000744	0.00273	CbGpPWpGaD
Crizotinib—CYP3A5—uterine cervix—vaginal cancer	0.000724	0.000995	CbGeAlD
Crizotinib—FGR—Hemostasis—IFNA1—vaginal cancer	0.000713	0.00262	CbGpPWpGaD
Crizotinib—LYN—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000689	0.00253	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—IFNA1—vaginal cancer	0.00067	0.00246	CbGpPWpGaD
Crizotinib—JAK3—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.00067	0.00246	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—IFNA1—vaginal cancer	0.000651	0.00239	CbGpPWpGaD
Crizotinib—JAK2—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000645	0.00237	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—IFNA1—vaginal cancer	0.000642	0.00236	CbGpPWpGaD
Crizotinib—LYN—Signaling by Interleukins—IL2—vaginal cancer	0.000611	0.00224	CbGpPWpGaD
Crizotinib—LYN—Immune System—EIF4A3—vaginal cancer	0.000602	0.00221	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EIF4A3—vaginal cancer	0.000599	0.0022	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—IFNA1—vaginal cancer	0.000593	0.00218	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—IFNA1—vaginal cancer	0.000593	0.00218	CbGpPWpGaD
Crizotinib—MAP3K3—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000588	0.00216	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—IFNA1—vaginal cancer	0.000584	0.00214	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—IFNA1—vaginal cancer	0.000576	0.00211	CbGpPWpGaD
Crizotinib—JAK2—Signaling by Interleukins—IL2—vaginal cancer	0.000572	0.0021	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000565	0.00207	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EIF4A3—vaginal cancer	0.000564	0.00207	CbGpPWpGaD
Crizotinib—JAK3—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000554	0.00204	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—IFNA1—vaginal cancer	0.000526	0.00193	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—IFNA1—vaginal cancer	0.000518	0.0019	CbGpPWpGaD
Crizotinib—LCK—Signaling by Interleukins—IL2—vaginal cancer	0.000501	0.00184	CbGpPWpGaD
Crizotinib—RIPK2—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000494	0.00181	CbGpPWpGaD
Crizotinib—LCK—Immune System—EIF4A3—vaginal cancer	0.000494	0.00181	CbGpPWpGaD
Crizotinib—CYP3A5—female gonad—vaginal cancer	0.000494	0.000678	CbGeAlD
Crizotinib—IRAK1—Innate Immune System—IFNA1—vaginal cancer	0.000492	0.00181	CbGpPWpGaD
Crizotinib—CYP3A5—vagina—vaginal cancer	0.000491	0.000674	CbGeAlD
Crizotinib—PTK2B—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000487	0.00179	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IFNA1—vaginal cancer	0.000484	0.00178	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—IFNA1—vaginal cancer	0.000477	0.00175	CbGpPWpGaD
Crizotinib—PTK2—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000468	0.00172	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IFNA1—vaginal cancer	0.000464	0.0017	CbGpPWpGaD
Crizotinib—TEK—Hemostasis—IL2—vaginal cancer	0.000458	0.00168	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IFNA1—vaginal cancer	0.000438	0.00161	CbGpPWpGaD
Crizotinib—SRC—Immune System—EIF4A3—vaginal cancer	0.000437	0.0016	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—IFNA1—vaginal cancer	0.000429	0.00158	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—IFNA1—vaginal cancer	0.000427	0.00157	CbGpPWpGaD
Crizotinib—CYP3A4—female reproductive system—vaginal cancer	0.000407	0.000559	CbGeAlD
Crizotinib—JAK2—Hemostasis—IFNA1—vaginal cancer	0.000402	0.00148	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IFNA1—vaginal cancer	0.00039	0.00143	CbGpPWpGaD
Crizotinib—ABCB1—epithelium—vaginal cancer	0.000388	0.000533	CbGeAlD
Crizotinib—LYN—Innate Immune System—IFNA1—vaginal cancer	0.000387	0.00142	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IFNA1—vaginal cancer	0.000385	0.00141	CbGpPWpGaD
Crizotinib—ABCB1—uterine cervix—vaginal cancer	0.000385	0.000529	CbGeAlD
Crizotinib—PTK2B—Immune System—IFNA1—vaginal cancer	0.000385	0.00141	CbGpPWpGaD
Crizotinib—YES1—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000382	0.0014	CbGpPWpGaD
Crizotinib—BLK—Immune System—IFNA1—vaginal cancer	0.000375	0.00138	CbGpPWpGaD
Crizotinib—FGR—Immune System—IFNA1—vaginal cancer	0.000374	0.00137	CbGpPWpGaD
Crizotinib—IRAK1—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000363	0.00133	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IFNA1—vaginal cancer	0.000362	0.00133	CbGpPWpGaD
Crizotinib—TXK—Immune System—IL2—vaginal cancer	0.000355	0.00131	CbGpPWpGaD
Crizotinib—ABCB1—urethra—vaginal cancer	0.000353	0.000486	CbGeAlD
Crizotinib—TYK2—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000352	0.00129	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—IFNA1—vaginal cancer	0.000352	0.00129	CbGpPWpGaD
Crizotinib—ABCB1—endometrium—vaginal cancer	0.000348	0.000478	CbGeAlD
Crizotinib—JAK3—Hemostasis—IL2—vaginal cancer	0.000345	0.00127	CbGpPWpGaD
Crizotinib—LYN—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000345	0.00126	CbGpPWpGaD
Crizotinib—ABCB1—Allograft Rejection—IL2—vaginal cancer	0.000337	0.00124	CbGpPWpGaD
Crizotinib—ABCB1—mammalian vulva—vaginal cancer	0.000336	0.000462	CbGeAlD
Crizotinib—STK4—Signaling Pathways—IL2—vaginal cancer	0.000332	0.00122	CbGpPWpGaD
Crizotinib—JAK2—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000322	0.00118	CbGpPWpGaD
Crizotinib—ABCB1—uterus—vaginal cancer	0.000321	0.000441	CbGeAlD
Crizotinib—LCK—Innate Immune System—IFNA1—vaginal cancer	0.000317	0.00116	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—IFNA1—vaginal cancer	0.000312	0.00114	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IFNA1—vaginal cancer	0.000306	0.00112	CbGpPWpGaD
Crizotinib—YES1—Immune System—IFNA1—vaginal cancer	0.000302	0.00111	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—IL2—vaginal cancer	0.000295	0.00108	CbGpPWpGaD
Crizotinib—ABCB1—female reproductive system—vaginal cancer	0.000288	0.000396	CbGeAlD
Crizotinib—IRAK1—Immune System—IFNA1—vaginal cancer	0.000286	0.00105	CbGpPWpGaD
Crizotinib—LYN—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000285	0.00105	CbGpPWpGaD
Crizotinib—LCK—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000282	0.00104	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—IL2—vaginal cancer	0.000282	0.00104	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IFNA1—vaginal cancer	0.000281	0.00103	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IFNA1—vaginal cancer	0.000278	0.00102	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—IL2—vaginal cancer	0.000269	0.000989	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—IL2—vaginal cancer	0.000268	0.000985	CbGpPWpGaD
Crizotinib—JAK2—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000267	0.00098	CbGpPWpGaD
Crizotinib—ABCB1—female gonad—vaginal cancer	0.000262	0.00036	CbGeAlD
Crizotinib—ABCB1—vagina—vaginal cancer	0.000261	0.000358	CbGeAlD
Crizotinib—SRC—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.00025	0.000918	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—IL2—vaginal cancer	0.000245	0.0009	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—IL2—vaginal cancer	0.000245	0.0009	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—IL2—vaginal cancer	0.000241	0.000887	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—IL2—vaginal cancer	0.000238	0.000874	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—IL2—vaginal cancer	0.000236	0.000867	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—IL2—vaginal cancer	0.000236	0.000867	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000234	0.000858	CbGpPWpGaD
Crizotinib—LYN—Immune System—IFNA1—vaginal cancer	0.000225	0.000827	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IFNA1—vaginal cancer	0.000224	0.000823	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—IL2—vaginal cancer	0.000224	0.000822	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—IL2—vaginal cancer	0.000218	0.000801	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IFNA1—vaginal cancer	0.000211	0.000774	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—IL2—vaginal cancer	0.000205	0.000752	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL2—vaginal cancer	0.0002	0.000735	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—IL2—vaginal cancer	0.000198	0.000728	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL2—vaginal cancer	0.000192	0.000705	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFNA1—vaginal cancer	0.000185	0.000678	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL2—vaginal cancer	0.000181	0.000665	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL2—vaginal cancer	0.000179	0.000657	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—IL2—vaginal cancer	0.000178	0.000652	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—IL2—vaginal cancer	0.000177	0.000649	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—IL2—vaginal cancer	0.000166	0.00061	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNA1—vaginal cancer	0.000163	0.0006	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL2—vaginal cancer	0.000162	0.000594	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL2—vaginal cancer	0.000161	0.000593	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL2—vaginal cancer	0.000159	0.000584	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL2—vaginal cancer	0.000158	0.000582	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL2—vaginal cancer	0.000155	0.00057	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL2—vaginal cancer	0.000155	0.000568	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—IL2—vaginal cancer	0.000146	0.000534	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—IL2—vaginal cancer	0.000129	0.000473	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL2—vaginal cancer	0.000127	0.000465	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL2—vaginal cancer	0.000126	0.000462	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL2—vaginal cancer	0.000125	0.000459	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL2—vaginal cancer	0.000118	0.000435	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL2—vaginal cancer	0.000117	0.00043	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL2—vaginal cancer	0.000115	0.000422	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—IL2—vaginal cancer	0.000105	0.000386	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL2—vaginal cancer	0.000104	0.000383	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL2—vaginal cancer	0.000103	0.000378	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL2—vaginal cancer	9.84e-05	0.000361	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL2—vaginal cancer	9.54e-05	0.00035	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL2—vaginal cancer	9.54e-05	0.00035	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2—vaginal cancer	9.31e-05	0.000342	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2—vaginal cancer	9.27e-05	0.00034	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—vaginal cancer	8.71e-05	0.00032	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—vaginal cancer	8.19e-05	0.000301	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—vaginal cancer	8.07e-05	0.000296	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—vaginal cancer	7.66e-05	0.000281	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—vaginal cancer	7.63e-05	0.00028	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—vaginal cancer	7.43e-05	0.000273	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—vaginal cancer	6.76e-05	0.000248	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—vaginal cancer	6.02e-05	0.000221	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—vaginal cancer	5.63e-05	0.000207	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—vaginal cancer	4.93e-05	0.000181	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—vaginal cancer	4.37e-05	0.00016	CbGpPWpGaD
